Causes and Risk Factors
RA develops when the immune system attacks the synovium, the thin membrane that lines the joints. The resulting inflammation thickens the synovium and can eventually erode cartilage and bone. Why this happens is not fully understood, but several factors increase risk:- Genetics: Certain inherited genes make the immune system more likely to react abnormally against the body's own tissues.
- Smoking: Cigarette smoking increases the risk of developing RA and tends to make the disease more severe and harder to treat.
- Sex and age: Women are affected two to three times more often than men, and onset is most common in middle age.
- Excess weight: Carrying extra weight modestly increases risk and can make treatment less effective.
Symptoms
Symptoms usually develop gradually over weeks to months and characteristically affect the same joints on both sides of the body:- Tender, warm, swollen joints: RA most often starts in the small joints of the hands, wrists, and the balls of the feet.
- Morning stiffness: Joint stiffness that lasts an hour or more after waking is a hallmark of inflammatory joint disease.
- Fatigue, low-grade fever, and loss of appetite: Because RA is a systemic disease, many people feel generally unwell, not just sore.
- Rheumatoid nodules: Firm, painless lumps may form under the skin, often near the elbows.
Diagnosis
There is no single test for RA. Your physician combines a careful joint examination with blood tests — including rheumatoid factor, anti-CCP antibodies, and inflammation markers such as the sedimentation rate and C-reactive protein — and imaging such as X-rays or ultrasound. Your physician may also order baseline blood counts and liver and kidney tests, since these are monitored regularly during treatment. Because other forms of inflammatory arthritis can look similar early on, careful evaluation matters. Early diagnosis is important: most joint damage begins within the first two years of the disease, and modern treatment can largely prevent it.Treatment
Treatment aims for remission — little or no active joint inflammation — and works best when started early:- Conventional DMARDs: Disease-modifying antirheumatic drugs such as methotrexate, hydroxychloroquine, and sulfasalazine slow the disease itself rather than just easing symptoms, and are the foundation of therapy.
- Biologic agents: TNF inhibitors such as adalimumab, etanercept, and infliximab, and other biologics such as abatacept, target specific immune pathways when conventional DMARDs are not enough.
- JAK inhibitors: Oral targeted medicines such as tofacitinib, upadacitinib, and baricitinib are another option for persistent disease.
- Symptom relief: NSAIDs and short courses of corticosteroids ease pain and swelling while the slower-acting medicines take effect.
- Lifestyle measures: Regular low-impact exercise, quitting smoking, and joint-protection techniques all improve long-term outcomes.
Living With Rheumatoid Arthritis
Rheumatoid arthritis is now a condition most people control rather than endure, but only when treatment is adjusted until inflammation is actually gone rather than merely improved. The details that follow are what separate remission from a lifetime of managed flares.
Remission is measured, not felt
Disease activity is scored at each visit from a joint count, a blood marker, and your own assessment, and treatment is escalated whenever the score misses the target, typically every one to three months until it is reached. Feeling better is not the goal; no swollen joints and a normal inflammatory marker is. Tapering is considered only after remission has held for six months or more, and slowly, because most people who stop treatment outright relapse within a year. The inflammatory arthritis page covers the rules for methotrexate and biologics that apply across all types.
Why the first drug is combined or switched
About half of people reach the target on methotrexate alone, often switched to the injectable form when tablets upset the stomach or the dose climbs. When it is not enough, adding hydroxychloroquine and sulfasalazine, or adding a biologic such as adalimumab or etanercept, are both effective, and the choice is made on cost, convenience, and other conditions. JAK inhibitors such as tofacitinib carry a warning about heart events and cancer in people over 50 with cardiovascular risk factors, so that history is reviewed before they are chosen.
The disease beyond the joints
Rheumatoid arthritis roughly doubles the risk of coronary artery disease, which is why cholesterol and blood pressure are treated more aggressively than the numbers alone would suggest. A new dry cough or breathlessness is checked for lung involvement rather than attributed to being unfit. Dry eyes and mouth, anemia of chronic inflammation, and osteoporosis from both inflammation and steroids are common enough to be screened for routinely.
Hands, feet, work, and weather
Occupational therapy, splints, and footwear that accommodates the forefoot preserve function and reduce pain more than most people expect, and a morning routine of warm water and gentle movement shortens the stiffness. Regular low-impact exercise reduces disease activity rather than aggravating it. Many patients report worse symptoms with the humidity and pressure swings here, which our arthritis and humidity guide addresses; our early warning signs article covers what to watch for in family members.
Pregnancy and family planning
Methotrexate is stopped at least three months before trying to conceive, for men as well as women, while hydroxychloroquine, sulfasalazine, and certain biologics are continued safely through pregnancy. The disease often quietens during pregnancy and flares afterward, so a plan for the months after delivery is made in advance. Our musculoskeletal team coordinates monitoring between rheumatology visits. The American College of Rheumatology and NIAMS publish patient guidance on treatment and daily life.
If your rheumatoid arthritis is better but not gone, or you have not had a disease activity score in the past three months, schedule a visit.